Shelby Rae Booker, DO
Obstetrics/Gynecology · Napa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 3
- 1 carrier
- Office
- 1
- Since medical school
- 9 years
- Michigan State University College of Osteopathic Medicine, 2017
Offices
1 location · Providence Medical Foundation · 1,461 clinicians in this group
Looking this up.
Hospitals listed: Providence Queen of the Valley Medical Center. That is not proof they admit you there this week.
Plans that list them
3 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Booker’s office at (707) 251-1850 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Providence Queen of the Valley Medical CenterNapa, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Providence, which runs 54 hospitals in 7 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.107, Oct 2024 – Sep 2025
See every measure and the patient survey for Providence Queen of the Valley Medical Center
Behind the star rating — Deaths: 0 better, 7 the same, 1 worse of 8 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 2 better, 9 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.107 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.9 (0 to 1.92) · 609 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.5 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 191.43 (130.54 to 252.33) · 39 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 9.1 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 135 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 12 · 271 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.7 · 376 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11 · 175 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 1,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.21 (0 to 0.41) · 4,152 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,188 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.81 (1.63 to 5.99) · 803 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.54 (0 to 3.21) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.19 (0.62 to 3.77) · 742 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.45 (0.91 to 16) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.58 (1.75 to 9.42) · 250 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.65 (0.17 to 3.13) · 152 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.19 (0 to 0.94) · 2,994 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.684 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.887 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.2 · 133 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 270 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.8 · 143 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -22.1 · 316 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -1 · 399 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 20.4 · 337 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.5 to 7.8) · 107 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 13.4 (9.8 to 17.7) · 107 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 76 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.4 to 16.2) · 848 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 423 cases | No different | Jan 2024 – Dec 2024 |
What patients said (449 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 1 |
| Recommend hospital | 4 |
| Room was "always" clean | 73% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 84% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 75% |
| Nurses "always" listened carefully | 76% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 40% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 41% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
Original Medicare doctor bills
$9,274
Medicare paid this office $9,274 for 51 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 21 | $1,672 | $62 |
| Return visit (30+ min) | 15 | $1,281 | $85 |
| New patient visit (30+ min) | 13 | $1,005 | $77 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
51 Original Medicare patients in 2024. Average age 71 · Women 100% · Also on Medicaid 22% · Health risk score 0.83. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 61%.
The office billed $41,922, Medicare allowed $13,553 and paid $9,274; for 96 services of 24 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 51 | 96 | 71 | 0.83 | $41,922 | $9,274 |
| 2023 | 54 | 118 | 71 | 1.18 | $47,354 | $13,107 |
| 2022 | 39 | 73 | 71 | 0.80 | $29,499 | $8,320 |
| 2021 | 18 | 38 | 67 | 0.91 | $10,166 | $3,816 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 3 services
| Return visit (30+ min) | 17 | $2,614 | $105 |
| Short return visit (20+ min) | 17 | $1,452 | $76 |
| New patient visit (30+ min) | 15 | $1,392 | $93 |
2022: 2 services
| Return visit (30+ min) | 15 | $1,979 | $104 |
| New patient visit (45+ min) | 13 | $1,257 | $97 |
Medicaid work
$14,306 in 2024
Medicaid paid $14,306 for 320 billed services this clinician did in 2024, up to 27 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Prenatal care, at-risk enhanced service; antepartum management | 123 | $10,787 |
| FETAL NON-STRESS TEST | 167 | $2,255 |
| Return visit (30+ min) | 16 | $843 |
| Short return visit (20+ min) | 14 | $421 |
| 2024 | 320 | 4 | 27 | $14,306 |
| 2023 | 342 | 4 | 28 | $23,569 |
| 2022 | 587 | 4 | 37 | $38,015 |
| 2021 | 289 | 5 | 43 | $21,262 |
See the largest Medicaid services in earlier years
2023
| Prenatal care, at-risk enhanced service; antepartum management | 217 | $19,031 |
| Return visit (30+ min) | 47 | $2,286 |
| Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses | 28 | $1,646 |
| FETAL NON-STRESS TEST | 50 | $606 |
2022
| Prenatal care, at-risk enhanced service; antepartum management | 391 | $34,291 |
| FETAL NON-STRESS TEST | 162 | $1,863 |
| Service | 17 | $931 |
| Return visit (30+ min) | 17 | $930 |
2021
| Prenatal care, at-risk enhanced service; antepartum management | 196 | $17,189 |
| Service | 41 | $2,237 |
| Ultrasound, pregnant uterus, real time with image documentation, limited (eg, fetal heart beat, placental location, fetal position and/or qualitative amniotic fluid volume), 1 or more fetuses | 14 | $881 |
| Short return visit (20+ min) | 20 | $737 |
| FETAL NON-STRESS TEST | 18 | $218 |
Drugs they prescribed that Part D paid
$6,499
Pharmacies billed $6,499 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
117 generic and fewer than 11 brand-name prescriptions · $6,499 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 37 | $2,368 | $64 |
| Clotrimazole-Betamethasone | 14 | $329 | $23 |
Year by year
| 2024 | 123 | 36 | None | None | $6,499 |
| 2023 | 106 | 39 | None | None | $7,354 |
| 2022 | 65 | 30 | None | None | $6,142 |
| 2021 | 35 | 19 | None | None | $846 |
| 2020 | 22 | 12 | None | None | $887 |
| 2019 | 14 | None | None | 0% | $194 |
| 2018 | 24 | 14 | None | 0% | $379 |
| 2017 | 15 | None | None | None | $148 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Estradiol | 18 | $1,186 | $66 |
| Clotrimazole-Betamethasone | 14 | $281 | $20 |
2022: 1 drug
| Estradiol | 20 | $3,069 | $153 |
Money from drug and device companies
$485 in 2025
| 2025 | 11 | 19 | None | $485 |
| 2024 | 10 | 13 | None | $404 |
| 2023 | 5 | 8 | None | $189 |
| 2022 | 2 | 3 | None | $60 |
| 2021 | 3 | 3 | None | $202 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Biocircuit Technologies | Nerve Tape | $97 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $70 | 3 payments
|
| Astellas Pharma US | Veozah | $64 | 3 payments
|
| Bayer Healthcare Pharmaceuticals | Lynkuet | $46 | 2 payments
|
| Organon | Nexplanon | $44 | 2 payments
|
| Conmed | Visiclear | $36 | 1 payment
|
See all 19 published payments
| Dexcom | Meals · 2025-11-26 | Dexcom G6 Transmitter | $34 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-11-20 | Lynkuet | $27 |
| Sumitomo Pharma America | Meals · 2025-11-12 | Myfembree | $21 |
| Organon | Meals · 2025-10-15 | Jada System | $22 |
| Mayne Pharma Commercial | Meals · 2025-10-08 | None | $7 |
| Mayne Pharma Commercial | Meals · 2025-09-16 | None | $8 |
| Astellas Pharma US | Meals · 2025-09-15 | Veozah | $15 |
| Mayne Pharma Commercial | Meals · 2025-08-26 | None | $7 |
| Amgen | Meals · 2025-07-16 | Evenity | $20 |
| Astellas Pharma US | Meals · 2025-06-25 | Veozah | $32 |
| Biocircuit Technologies | Meals · 2025-05-24 | Nerve Tape | $97 |
| Sumitomo Pharma America | Meals · 2025-05-21 | Myfembree | $23 |
| Astellas Pharma US | Meals · 2025-04-28 | Veozah | $17 |
| Biogen | Meals · 2025-04-10 | Zurzuvae | $30 |
| Conmed | Meals · 2025-03-26 | Visiclear | $36 |
| Lilly USA | Meals · 2025-02-12 | Zepbound | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-01-30 | Mirena | $19 |
| Organon | Meals · 2025-01-22 | Nexplanon | $22 |
| Sumitomo Pharma America | Meals · 2025-01-08 | Myfembree | $25 |
See earlier years (2024, 2023, 2022, 2021)
2024: $404
| Mayne Pharma Commercial | Nextstellis | $123 | 1 payment
|
| Astellas Pharma US | Veozah | $63 | 2 payments
|
| Abbvie | Liletta | $58 | 2 payments
|
| Hologic Sales and Service | Fluent Fluid Management System | $37 | 1 payment
|
| Minerva Surgical | None | $24 | 1 payment
|
| Organon | Nexplanon | $21 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $20 | 1 payment
|
| Sumitomo Pharma America | Myfembree | $20 | 1 payment
|
| Ethicon US | Enseal X1 | $19 | 1 payment
|
| Avanos Medical | On-Q* Pump and Accessories | $19 | 1 payment
|
2023: $189
| Astellas Pharma US | Veozah | $63 | 2 payments
|
| Sumitomo Pharma America | Myfembree | $45 | 2 payments
|
| Organon | Nexplanon | $34 | 2 payments
|
| AbbVie | Orilissa | $28 | 1 payment
|
| Pfizer | Premarin | $19 | 1 payment
|
2022: $60
| Abbvie | Orilissa | $46 | 2 payments
|
| Pfizer | Premarin | $14 | 1 payment
|
2021: $202
| AbbVie | Oriahnn | $99 | 1 payment
|
| Abbott Laboratories | Proclaim Ipg | $81 | 1 payment
|
| Mylan Pharmaceuticals | Xulane | $22 | 1 payment
|
Professional record
- NPI
- 1831626381
- Licence
- CA 20A18789, MI INPROGRESS
- Trained
- Michigan State University College of Osteopathic Medicine, 2017 · 9 years ago
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 1100 Trancas St Ste 209, Napa, CA, 94558
- NPI first listed
- 2017-05-15
- NPI last updated
- 2022-07-21
- NPI record certified
- 2021-10-15
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 44405 Woodward Ave, Pontiac, MI, 48341
This office lists an electronic records connection.